A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Drug rashes can be an unwanted side effect of many medications. Learn which medications can cause these skin reactions.

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

The Pine Bluff Police Department is now investigating multiple pharmacy burglaries, including one where thieves took a ...

A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian ...

The first patient with relapsed or refractory acute myeloid leukemia has been dosed with Annamycin plus Cytarabine in the ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

(Some types of chemotherapy contain the element platinum.) The researchers also noted "significant improvement" in overall survival with this combination of drugs. Relacorilant, which is ...